Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of Herceptin in HER2-overexpressing metastatic breast cancer
jRCT1080220021Phase 4
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on jRCT1080220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220021.